Department of Obstetrics and Gynecology, University Hospitals Case Medical Center, Cleveland, OH 44106, USA.
Gynecol Oncol. 2011 Nov;123(2):351-5. doi: 10.1016/j.ygyno.2011.07.028.
To estimate the prevalence of sleep disturbances, and to determine if there is an association between sleep disturbances with quality of life (QOL), depression or clinical demographic variables.
Patients diagnosed with ovarian, fallopian tube or primary peritoneal cancer during the last 5years completed questionnaires regarding sleep patterns and disturbances [Pittsburgh Sleep Quality Index (PSQI)], depression [Beck Depression inventory (BDI)], and QOL [The Functional Assessment of Cancer Therapy-Ovarian (FACT-O), fatigue module (-F)]. Data were analyzed by Student's t-test or Pearson correlation coefficient to determine if there were differences between PSQI score with QOL, depression or clinical demographic variables.
86/275 (31% response) of patients returned the surveys. Mean age was 58.1 (SD=14.6) years and 70% had advanced disease at diagnosis. Thirty-six percent had current disease of which 81% were receiving chemotherapy. Sixty-seven percent of patients had a PSQI score≥5 corresponding to overall poor sleep quality and 46% of patients reported using sleep medication at least once during the prior month. PSQI score was significantly inversely correlated with all QOL domains (physical: r=-.599, p<.001, functional: r=-.692, p<.001, social: r=-.212, p<.001, emotional: r=-.379, p<.001, fatigue; r=-.655 p<.001) and with depression (r=.539, p<.001). PSQI was not correlated with age, time since diagnosis, number of previous chemotherapy regimens. PSQI score did not differ by current disease or chemotherapy status.
Sleep disturbances reduce QOL, a prognostic indicator for survival, in ovarian cancer patients. These patients should undergo routine screening and would benefit from interventions that aim to promote restful sleep.
评估睡眠障碍的发生率，并确定睡眠障碍与生活质量（QOL）、抑郁或临床人口统计学变量之间是否存在关联。
在过去 5 年内被诊断患有卵巢癌、输卵管癌或原发性腹膜癌的患者完成了关于睡眠模式和障碍的问卷[匹兹堡睡眠质量指数（PSQI）]、抑郁[贝克抑郁量表（BDI）]和生活质量[癌症治疗功能评估卵巢问卷（FACT-O），疲劳模块（-F）]。通过学生 t 检验或 Pearson 相关系数分析数据，以确定 PSQI 评分与生活质量、抑郁或临床人口统计学变量之间是否存在差异。
86/275（31%的应答率）名患者返回了调查问卷。平均年龄为 58.1（SD=14.6）岁，70%的患者在诊断时处于晚期疾病状态。36%的患者有当前疾病，其中 81%正在接受化疗。67%的患者 PSQI 评分≥5，对应整体睡眠质量差，46%的患者报告在过去一个月至少使用过一次睡眠药物。PSQI 评分与所有生活质量领域（身体：r=-.599，p<.001，功能：r=-.692，p<.001，社会：r=-.212，p<.001，情感：r=-.379，p<.001，疲劳：r=-.655，p<.001）和抑郁（r=.539，p<.001）呈显著负相关。PSQI 与年龄、诊断后时间、之前化疗方案的数量无关。PSQI 评分不因当前疾病或化疗状态而有所不同。
睡眠障碍降低了卵巢癌患者的生活质量，这是生存的预后指标。这些患者应进行常规筛查，并受益于旨在促进睡眠的干预措施。
